A 2015 Congressional amendment precludes Mitochondrial Replacement Therapy (MRT), a life-saving IVF-based procedure that could prevent a plethora of mitochondrial DNA diseases in the U.S. Individuals do not, at present, have access to this technology to prevent the devastating consequences of mitochondrial DNA disease. At the same time, MRT continues to move forward in other countries, such as the UK.
Has the time come to revisit the federal prohibition of this preventive therapy and research?
Expert panelists discussed the future of MRT policy in the U.S., reviewing the latest technological developments, the regulatory barriers, and the ethical challenges affecting the clinical application of MRT.
This event was free and open to the public.
Sponsored by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School.